| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3335956 | Transfusion and Apheresis Science | 2008 | 10 Pages |
Abstract
Methylene blue (MB) treated plasma has been in clinical use for 15 years. The current Theraflex MB-Plasma system has a number of improved features compared with the original Springe methodology. This article gives an overview of processing methodology and recent developments, pathogen inactivation capacity, pharmacokinetics and toxicology, effects on plasma proteins and storage stability, clinical experience and future perspectives. Emphasises will be placed on most recent literature and updated information available.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Jerard Seghatchian, Wolfram H. Walker, Stefan Reichenberg,